Akebia Therapeutics, Inc. (AKBA) income statement
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.41+0.01 (+2.12%)
Close on Nov 18, 2026Market cap $113.31MP/E –Yield –
Akebia Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 79.6%
- Operating margin
- -6.9%
- Net margin
- -13.5%
- Return on equity, FY2025
- 64.5%
Financial strength
- Current ratio
- 1.43
- Debt to equity
- 1.98
- Debt to assets
- 14.2%
- Cash to current liabilities
- 96.7%
Valuation
- P/E ratio
- –
- Price to sales
- 0.52
- Price to book
- 4.53
- Dividend yield
- –
See a number that looks wrong?